MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$38,680K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturities and red...
Stock-based compensation expense
Accounts payable
Others
Negative Cash Flow Breakdown
Purchases of equity investments,...
Purchases of short-term investme...
Accounts receivable, net
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-21,168
-20,393
-589
-21,165
Depreciation and amortization expense
4,470
4,504
4,495
4,493
Amortization of debt issuance costs
808
576
446
444
Provision for expected credit losses
3,249
2,109
2,733
3,168
Operating lease and other impairment charges
0
0
0
0
Amortization of discount or (accretion of premium) on short-term investments
1,074
747
1,745
303
Loss from equity method investment
-5,641
-
-
-
Stock-based compensation expense
15,740
15,660
20,110
21,141
Loss on extinguishment of debt
-
-
0
0
Acquired in-process research and development expenses
0
0
0
0
Other
-799
1,804
3,322
617
Accounts receivable, net
25,762
-22,680
42,014
1,282
Inventories
10,491
-1,927
-7,564
-5,194
Prepaid and other current assets
-495
18,997
-3,052
9,792
Other long-term assets
2,613
8,521
10,473
-61
Accounts payable
9,746
13,754
5,818
-9,330
Accrued expenses
-
-
-664
-
Employee-related liabilities
-2,329
-14,743
5,798
12,846
Deferred revenue
-2,704
-1,078
-686
-1,392
Operating leases and other current liabilities
-3,797
7,892
10,208
614
Other long-term liabilities
-4,042
762
-2,139
226
Net cash used in operating activities
-34,630
11,054
9,789
8,264
Purchases of short-term investments
44,382
216,130
29,656
29,508
Proceeds from maturities and redemptions of short-term investments
42,523
26,950
56,489
54,136
Purchases of property and equipment
4,050
6,268
6,685
4,092
Acquisition of in-process research and development
0
0
35,124
0
Purchases of equity investments, strategic investments, and intangible assets
81,427
-
0
-
Net cash provided by (used in) investing activities
-87,336
-195,448
-14,976
20,536
Proceeds from issuance of convertible senior notes due 2032, net of 8,843 debt issuance costs
0
291,157
0
0
Repurchase of 246,740 principal amount of convertible senior notes due 2025
-
-
0
0
Principal payments on convertible senior notes due 2025
0
-
0
0
Payment for capped call transactions related to convertible senior notes due 2032
0
15,300
0
0
Repurchase and retirement of common stock
-
-
0
0
Cash used to settle withholding taxes on vested restricted stock, net of proceeds from issuance of common stock under company stock plans
-2,154
1,696
-2,604
5,211
Other financing activities
-
-
0
0
Net cash provided by (used in) financing activities
2,154
274,161
2,604
-1,570
Effect of foreign exchange rate changes on cash
3,305
-1,076
1,270
605
Net decrease in cash and cash equivalents
-116,507
88,691
-1,313
27,835
Cash and cash equivalents at beginning of period
179,325
90,634
91,947
69,234
Cash and cash equivalents at end of period
62,818
179,325
90,634
91,947
Income taxes (refunded) paid
1,758
-
-
-
Operating lease right-of-use assets obtained in exchange for operating lease obligations
10,224
-
-
-
Purchases of property and equipment included in accounts payable and accrued expenses
1,851
-
-
-
Intangible costs in other long-term liabilities
13,300
-
-
-
Loss from equity method investment
-5,635
-3,865
-4,553
-2,724
Unamortized debt issuance costs
13,673
-
-
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Cash used to settle
withholding taxes on vested...
-$2,154K
(-159.16%↓ Y/Y)
Effect of foreign
exchange rate changes on...
$3,305K
(1356.65%↑ Y/Y)
Net cash provided by
(used in) financing...
$2,154K
(104.85%↑ Y/Y)
Net decrease in cash
and cash...
-$116,507K
(-2174.64%↓ Y/Y)
Canceled cashflow
$5,459K
Proceeds from maturities
and redemptions of...
$42,523K
(-70.96%↓ Y/Y)
Stock-based compensation
expense
$15,740K
(-69.22%↓ Y/Y)
Accounts payable
$9,746K
(69.82%↑ Y/Y)
Loss from equity
method investment
-$5,641K
(18.45%↑ Y/Y)
Depreciation and
amortization expense
$4,470K
(-48.49%↓ Y/Y)
Provision for expected
credit losses
$3,249K
(-9.17%↓ Y/Y)
Amortization of debt issuance
costs
$808K
(-16.70%↓ Y/Y)
Prepaid and other
current assets
-$495K
(-121.08%↓ Y/Y)
Net cash provided by
(used in) investing...
-$87,336K
(-229.74%↓ Y/Y)
Net cash used in
operating activities
-$34,630K
(-24.68%↓ Y/Y)
Canceled cashflow
$42,523K
Canceled cashflow
$40,149K
Purchases of equity
investments, strategic...
$81,427K
Purchases of short-term
investments
$44,382K
(67.50%↑ Y/Y)
Accounts receivable, net
$25,762K
(90.60%↑ Y/Y)
Net loss
-$21,168K
(88.43%↑ Y/Y)
Purchases of property and
equipment
$4,050K
(-55.84%↓ Y/Y)
Inventories
$10,491K
(187.00%↑ Y/Y)
Other long-term
liabilities
-$4,042K
(-183.32%↓ Y/Y)
Operating leases and other
current liabilities
-$3,797K
(-145.19%↓ Y/Y)
Deferred revenue
-$2,704K
(0.22%↑ Y/Y)
Other long-term
assets
$2,613K
(174.15%↑ Y/Y)
Employee-related liabilities
-$2,329K
(81.59%↑ Y/Y)
Amortization of discount or
(accretion of premium) on...
$1,074K
(-39.66%↓ Y/Y)
Other
-$799K
(-288.44%↓ Y/Y)
Buy us a coffee
TANDEM DIABETES CARE INC (TNDM)
TANDEM DIABETES CARE INC (TNDM)